Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZOE.L Regulatory News (ZOE)

  • There is currently no data for ZOE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

26 Mar 2020 07:00

RNS Number : 6397H
Zoetic International PLC
26 March 2020
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

26 March 2020

 

Zoetic International plc

("Zoetic" or the "Company")

 

Issue of Equity

 

Zoetic, the London listed vertically integrated CBD company, is pleased to announce that Ox Distributing, LLC ("Ox Distributing") has subscribed for 23,750,000 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at a price of 5 pence each for a total consideration of £1,187,500 (the "Subscription").

 

Ox Distributing, which is owned by the Schrader family, is Zoetic's primary distribution partner in the United States and is part of the same group that owns the Schrader Oil convenience stores through which Zoetic's Chill products are sold. The Subscription was facilitated by the exercise of 23,750,000 warrants by Robert Price, the Company's former CEO, at 5 pence each. Mr Price agreed that the Company could issue the ordinary shares to Ox Distributing in lieu of payment by him for the warrant exercise.

 

In recognition that Zoetic's share price has been volatile during the current Covid-19 crisis and that the Company's Ordinary Shares have traded at below 5 pence this week, Zoetic and Ox Distributing have entered into a loan note instrument pursuant to which Ox Distributing will settle the consideration for the Subscription in 10 equal instalments of £118,750 each between 30 April 2020 and 31 January 2021. Ox Distributing may, at its discretion, elect to settle the consideration more quickly. The loan note instrument provides that interest will accrue on the outstanding consideration until such time as it is settled and, furthermore, a penalty interest rate will apply in the event that any monthly instalments are missed or delayed.

 

In a separate transaction, a second warrant holder has exercised 60,000 warrants, also at 5 pence each. Zoetic has also agreed with this warrant holder that he may pay for the resulting 60,000 ordinary shares over 10 months on similar terms to the loan note with Ox Distributing.

 

A further 2,750,000 warrants have expired unexercised. The Company now has no further warrants or options in issue aside from 7,155,000 share option awards to staff, exercisable at 10 pence per Ordinary Share, and 1,000,000 share options granted to Stephen Goldman, exercisable at 12 pence per Ordinary Share.

 

Application will be made for an additional 23,810,000 ordinary shares in the Company (the "New Ordinary Shares") to be admitted to trading on the Official List of the UK Listing Authority by way of a Standard Listing and to trading on the London Stock Exchange's Main Market for listed securities ("Admission"). Admission is expected to take place on 1 April 2020.

 

Following Admission, the New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares in issue, including the right to receive all dividends and other distributions declared, and the total number of Ordinary Shares with voting rights will be 172,920,034. This figure may be used by Zoetic International shareholders as the denominator for calculations to determine if they have a notifiable interest in Zoetic International under the Disclosure and Transparency Rules, or if such interest has changed.

 

Following Admission, the Schrader family's holding of 24,750,000 ordinary shares will represent 14.31% of the Company's total voting rights and Robert Price's existing holding of 11,440,000 ordinary shares will represent 6.62% of the Company's total voting rights.

 

Director remuneration and staff responsibilities

 

Following on from the cost savings announced last week, Paul Mendell, Zoetic's Chairman, has informed the Company that he will continue to waive any remuneration for his role. Furthermore, for the duration of the Covid-19 crisis and whilst the Company is running on a lower headcount and at a lower cost, several members of staff have been asked to take on additional responsibilities to cover work done by former members of the team. No one is receiving any additional remuneration for these additional responsibilities.

 

Nick Tulloch, Chief Executive of Zoetic, said:

 

"On behalf of the entire Zoetic team, I would like to thank Ox Distributing and the Schrader family for their support. In the midst of one of the greatest economic and health crises in memory, and when many investors are being highly cautious about entering into new commitments, the confidence they are showing in our ability to succeed in our business plan is truly flattering.

 

"As I mentioned in our update last week, with our two CBD brands and inventory of feminised hemp seeds, we were poised to make significant advances in our business this month. The challenges presented by Covid-19 mean that we need to reassess our timing, but we continue to work on the basis that it is a case of when and not if. This new financial support has given us far greater scope to navigate our Company through these difficult times."

 

**ENDS**

 

Enquiries

 

Zoetic International plc +44 (0) 1738 472 029

Nick Tulloch

 

Allenby Capital Limited (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Harriss

Nick Naylor

 

IFC Advisory Ltd (Financial PR and IR) +44 (0) 20 3934 6630

Tim Metcalfe

Graham Herring

Florence Chandler

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOELELLLBXLXBBK
Date   Source Headline
25th Jun 20204:00 pmRNSHolding(s) in Company
24th Jun 20203:00 pmRNSHolding(s) in Company
22nd Jun 20207:00 amRNSHolding(s) in Company
15th Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20209:05 amRNSSecond Price Monitoring Extn
3rd Jun 20209:00 amRNSPrice Monitoring Extension
2nd Jun 20207:00 amRNSSubscription for Equity
1st Jun 20207:00 amRNSNew Distribution Agreement and Trading Update
29th May 20207:00 amRNSFiling of Patents
27th May 20207:00 amRNSSale of DTU Interest and Kansas Nitrogen Assets
15th May 20207:00 amRNSTrading Update
11th May 20203:36 pmRNSHolding(s) in Company
6th May 20202:34 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSBoard and Strategy Changes, and Trading Update
3rd Apr 20207:00 amRNSIssue of Equity
1st Apr 20207:00 amRNSCOVID-19 Update
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
26th Mar 20207:00 amRNSIssue of Equity
20th Mar 20207:00 amRNSCOVID-19 Update
5th Mar 20207:00 amRNSOperational update
12th Feb 20207:00 amRNSSubscription to raise £0.39 million
5th Feb 20207:00 amRNSTrading Update
23rd Dec 20197:00 amRNSInterim Results
16th Dec 20197:00 amRNSSettlement of Diversion Debt & Notice of Results
28th Nov 20197:00 amRNSResult of General Meeting
25th Nov 20197:00 amRNSTrading Update
14th Nov 20199:19 amRNSIssue of Equity
13th Nov 20192:06 pmRNSSecond Price Monitoring Extn
13th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSListing on the OTC
8th Nov 20199:01 amRNSIssue of Equity
7th Nov 20197:00 amRNSNotice of General Meeting
1st Nov 20192:05 pmRNSSecond Price Monitoring Extn
1st Nov 20192:00 pmRNSPrice Monitoring Extension
29th Oct 20194:42 pmRNSSecond Price Monitoring Extn
29th Oct 20194:35 pmRNSPrice Monitoring Extension
21st Oct 20197:00 amRNSIssue of Shares
18th Oct 201911:05 amRNSSecond Price Monitoring Extn
18th Oct 201911:00 amRNSPrice Monitoring Extension
8th Oct 20197:00 amRNSAdoption of new share option scheme
4th Oct 20197:00 amRNSTrading Update
17th Sep 20197:00 amRNSDirectorate Change
12th Sep 201912:30 pmRNSDirector/PDMR Shareholding
9th Sep 201911:15 amRNSChange of Name
6th Sep 201910:30 amRNSDirector/PDMR Shareholding
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
4th Sep 20197:00 amRNSDirectorate Change
30th Aug 20194:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.